At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE:LLY) and Incyte Corp (NASDAQ:INCY) shared a 52-week analysis of Olumiant (baricitinib) in adults with severe alopecia areata, unpredictable, patchy hair loss.

• Patients who took Olumiant achieved significant scalp, eyelash, and eyebrow hair regrowth, and nearly 75% of those who responded to Olumiant 4-mg achieved 90% scalp coverage at 52 weeks.
• In February, the FDA granted priority review for Olumiant in severe AA as a potential first-in-disease medicine. 
• Lilly expects regulatory decisions in the U.S., European Union, and Japan in 2022.
• In the pooled 52-week analysis, two out of five patients who took Olumiant 4-mg (39.0%, n=201/515) achieved significant scalp hair regrowth, defined as 80% or more scalp hair coverage. Nearly three out of four patients (74.1%, n=149/201) achieved 90% hair coverage at 52 weeks. 
• More than two out of five patients saw full regrowth or regrowth with minimal gaps in eyebrow and eyelash hair.
• Among patients who took Olumiant 2-mg, more than one out of five (22.6%, n=77/340) achieved significant scalp hair regrowth, and two out of three (67.5%, n=52/77) gained 90% or more hair coverage at 52 weeks. 
• Price Action: INCY shares closed 0.35% higher at $78.46, and LLY stock closed at $289.02 on Friday.